Advertisement
- United States
- /
- Biotech
- /
- NasdaqGS:SWTX
SpringWorks Therapeutics Full Year 2024 Earnings: EPS Misses Expectations
SpringWorks Therapeutics (NASDAQ:SWTX) Full Year 2024 Results
Key Financial Results
- Revenue: US$191.6m (up by US$186.1m from FY 2023).
- Net loss: US$258.1m (loss narrowed by 21% from FY 2023).
- US$3.48 loss per share (improved from US$5.15 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
SpringWorks Therapeutics EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 14%.
Looking ahead, revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are up 2.3% from a week ago.
Risk Analysis
It is worth noting though that we have found 1 warning sign for SpringWorks Therapeutics that you need to take into consideration.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:SWTX
SpringWorks Therapeutics
A commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer.
Flawless balance sheet with high growth potential.
Similar Companies
Market Insights
Advertisement
Weekly Picks
WE
WealthAP on PayPal Holdings ·
The "Sleeping Giant" Stumbles, Then Wakes Up
Fair Value:US$8227.1% undervalued
16 followersusers have followed this narrative
1 commentusers have commented on this narrative
9 likesusers have liked this narrative
WO
woodworthfund on Bumble ·
Swiped Left by Wall Street: The BMBL Rebound Trade
Fair Value:US$960.0% undervalued
7 followersusers have followed this narrative
0 commentsusers have commented on this narrative
4 likesusers have liked this narrative
WE
WealthAP on Duolingo ·
Duolingo (DUOL): Why A 20% Drop Might Be The Entry Point We've Been Waiting For
Fair Value:US$268.6433.4% undervalued
20 followersusers have followed this narrative
3 commentsusers have commented on this narrative
2 likesusers have liked this narrative
Recently Updated Narratives
BA
bactrian on Novo Nordisk ·
A Quality Compounder Marked Down on Overblown Fears
Fair Value:US$9540.8% undervalued
95 followersusers have followed this narrative
8 commentsusers have commented on this narrative
1 likeusers have liked this narrative
YI
yiannisz on Etsy ·
Etsy Stock: Defending Differentiation in a World of Infinite Marketplaces
Fair Value:US$64.454.7% undervalued
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
YI
yiannisz on Align Technology ·
Align Technology Stock: Premium Orthodontics in a Cost-Sensitive World
Fair Value:US$154.628.4% overvalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Popular Narratives
AG
Agricola on Excellon Resources ·
A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).
Fair Value:CA$31.898.3% undervalued
69 followersusers have followed this narrative
12 commentsusers have commented on this narrative
21 likesusers have liked this narrative
AL
AlexLovell on Rocket Lab ·
Early mover in a fast growing industry. Likely to experience share price volatility as they scale
Fair Value:US$16.25429.4% overvalued
71 followersusers have followed this narrative
1 commentusers have commented on this narrative
18 likesusers have liked this narrative
AN
AnalystConsensusTarget on NVIDIA ·
NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
Fair Value:US$253.0226.0% undervalued
1022 followersusers have followed this narrative
6 commentsusers have commented on this narrative
28 likesusers have liked this narrative
Trending Discussion
ST
StevenM on Excellon Resources ·
Interesting analysis, but the price trajectory assumed for the baseline metals is problematic. These assumptions form the foundation for the entire case, and when compared against historical pricing, don’t appear to be grounded in any reasonable precedent. Even accounting for past commodity super-cycles, inflationary periods, or supply constraints, the forecasted pricing for gold, silver, zinc, and lead are well outside what history would suggest is plausible over comparable timeframes. That creates a fragile premise as the conclusions are driven by aggressive inputs rather than underlying market behavior that is realistic. The analysis would be materially stronger if the price assumptions were anchored to historical ranges and prior cycle peaks, with explicit rationale where the model intentionally departs from those patterns. As it stands, the trajectory feels more aspirational than analytical.
1
|1